NASDAQ: FRLNFreeline Therapeutics Holdings PLC Stock
$0.42-0.07 (-14.29%)
Updated Mar 22, 2023
FRLN Price
$0.42
Fair Value Price
$2.00
Market Cap
$27.29M
52 Week Low
$0.39
52 Week High
$1.29
P/E
-0.2x
P/B
0.4x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$100.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.46
Operating Cash Flow
-$76M
Beta
0.71
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A
FRLN Overview
Freeline Therapeutics Holdings plc is a clinical-stage biotechnology company developing adeno-associated virus vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. The company was founded in 2015 and is headquartered in Stevenage, U.K.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FRLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FRLN ($0.42) is undervalued by 78.98% relative to our estimate of its Fair Value price of $2.00 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FRLN ($0.42) is significantly undervalued by 78.98% relative to our estimate of its Fair Value price of $2.00 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
FRLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FRLN due diligence checks available for Premium users.
Be the first to know about important FRLN news, forecast changes, insider trades & much more!
FRLN News
Valuation
FRLN fair value
Fair Value of FRLN stock based on Discounted Cash Flow (DCF)
Price
$0.42
Fair Value
$2.00
Undervalued by
78.98%
FRLN ($0.42) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FRLN ($0.42) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FRLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FRLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
16.9x
Market
22.44x
FRLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.4x
Industry
4.76x
FRLN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FRLN's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.9M
Profit Margin
0%
FRLN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$100.1M
Liabilities
$31.5M
Debt to equity
0.46
FRLN's short-term assets ($74.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FRLN's short-term assets ($74.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FRLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.2M
Investing
-$2.2M
Financing
-$3.0k
FRLN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FRLN vs Biotech Stocks
Freeline Therapeutics Holdings Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.